Phase 4 N=1,299 Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
Bipolar Disorder
Primary: Change in BMI Z-score From Baseline to Month 6 in ITT Sample — -0.08; 0.00 Z-score — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Cardiovascular Effects of Adderall in Healthy Adults.
Hemodynamics · Cardiovascular System
Primary: Systolic Blood Pressure — 116; 116; 126; 115 mmHg
Phase 4 N=29 Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Parkinson Disease Psychosis
Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001
Phase 4 N=30 Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Dry Eye
Primary: Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to…
Phase 4 N=61 Evaluation of Pupil Dilation Speed With the MAP Dispenser
Mydriasis
Primary: Mean Change in Pupil Diameter From Baseline — 4.55; 4.88 millimeters
Phase 4 N=168 A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Asthma · Severe Eosinophilic Asthma
Primary: Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period — 0.151; 0.168; 0.605 Proportion of Participants
Phase 4 N=538 Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain
Low Back Pain
Primary: Time to First Achieve a Numeric Rating Scale-Pain Intensity Score <4 or a Pain Intensity Reduction of ≥30% From Drug Intake Till 8 Hours After the First Dose — 105; 120…
Phase 4 N=70 Stacking Exercises Aid the Decline in FVC and Sick Time
Duchenne Muscular Dystrophy
Primary: Change in FVC (%-Predicted) From Baseline to 2 Years. — -9.2; -6.4 Mean difference in FVC %-predicted — p=0.68
Phase 4 N=81 Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
Barotrauma;Ear
Primary: Requirement of Oxymetalozine Rescue for Ear Pain During Hyperbaric Therapy Compression — 8; 11 Participants
Phase 4 N=27 Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
Harm Reduction · HIV Infections · Drug Use
Primary: Percentage of Participants With HIV Viral Load Suppression — 11 Participants
Phase 4 N=140 An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Sickle Cell Disease (SCD)
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) — 3; 3 Participants
Phase 4 N=191 Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate
Chronic Uncontrolled Gout · Gout · Uncontrolled Gout
Primary: Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24 — 6.0; 0; 12.9 Percentage of…
Phase 4 N=88 Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Opioid Use Disorder
Primary: Area Under the Plasma Concentration-time Curve From Study Day 1 to Day 29 (AUC0-28days) of Buprenorphine — 1640; 1720; 1570; 1870 h*ng/mL
Phase 4 N=7 The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine
Vitamin B1 Deficiency · Thiamine Deficiency
Primary: Maximum Concentration (Cmax) of Thiamine in Plasma Between the Combination Arm(s) and Single Agent Arm — 15; 32 nM
Phase 4 N=305 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children
Uncomplicated Plasmodium Falciparum Malaria
Primary: AUC0-21d — 144; 205; 259; 318 hr*ug/mL